← back to search

Martin Ellis

Clalit Health Services · IL
Area of research
Internal Medicine · Genetics
Research interest
Research interests include Venous Thromboembolism Diagnosis and Management, Myeloproliferative Neoplasms: Diagnosis and Treatment, Atrial Fibrillation Management and Outcomes, and Blood transfusion and management.
h-index
37
citations
4,264
works
240
NIH funding
primary concept
Medicine
email

Recent publications

Prothrombin complex concentrate for oral factor Xa inhibitor reversal prior to urgent invasive procedures.
2026cited by 0position: contributordoi
Polycythemia vera
Mayo Clinic Proceedings 2026cited by 0position: contributordoi
Fedratinib for the treatment of myelofibrosis: a critical appraisal of clinical trial and "real-world" data.
2025cited by 6position: contributordoi
The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma.
2025cited by 5position: contributordoi
Vitamin K Antagonist Anticoagulation in Antiphospholipid Syndrome: Time in Therapeutic Range and Clinical Outcomes.
2025cited by 1position: contributordoi
Weathering the HLH storm and redesigning clinical trials.
2025cited by 0position: contributordoi
Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis
Blood 2024cited by 23position: middledoi
Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group.
2024cited by 3position: contributordoi
My First Patient.
2024cited by 0position: contributordoi
Queries regarding the two papers each reporting on 1000 essential thrombocythemia patients in BCJ.
2024cited by 0position: contributordoi
Direct Oral Anticoagulants in Special Patient Populations
Journal of Clinical Medicine 2023cited by 7position: middledoi
Challenges in Implementing Guideline on Integrative Oncology and Pain: The Israeli Perspective
Journal of Pain and Symptom Management 2023cited by 4position: middledoi
Use of direct oral anticoagulants in hematologic malignancies
Thrombosis Update 2023cited by 4position: contributordoi
An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis
Blood 2021cited by 144position: middledoi
COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome
Leukemia & lymphoma/Leukemia and lymphoma 2021cited by 33position: middledoi
Decision-Making in the Management of Venous Thromboembolism.
2021cited by 0position: contributordoi
D-dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry.
2020cited by 8position: contributordoi
Illustrated State‐of‐the‐Art Capsules of the ISTH 2020 Congress
Research and Practice in Thrombosis and Haemostasis 2020cited by 3position: middledoi
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases
American Journal of Hematology 2019cited by 70position: middledoi
Electronic patient identification for sample labeling reduces wrong blood in tube errors
Transfusion 2018cited by 62position: middledoi
Targeted next generation sequencing for the diagnosis of patients with rare congenital anemias
European Journal Of Haematology 2018cited by 41position: middledoi
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms
Blood Cancer Journal 2018cited by 37position: middledoi
Ethnic variation in medical and lifestyle risk factors for B cell non-Hodgkin lymphoma: A case-control study among Israelis and Palestinians
PLoS ONE 2017cited by 21position: middledoi
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients
Blood Cancer Journal 2016cited by 102position: middledoi
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)—ViLen-01 protocol
Annals of Hematology 2016cited by 6position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 12 papers (2020–2026)Pia Raanani · Tel Aviv University3 papers (2016–2025)Swaminathan P. Iyer · The University of Texas MD Anderson Cancer Center2 papers (2021–2025)Michael B. Jordan · Universidad Cervantina2 papers (2021–2025)Arnon Nagler · University of Naples Federico II2 papers (2017–2021)Joanne Yacobovich · Zero to Three2 papers (2018–2021)Sarah Nikiforow · Harvard University2 papers (2021–2025) · 1 papers (2023–2023) · 1 papers (2016–2016)Adi Zoref‐Lorenz · Children's Medical Center1 papers (2021–2021)Yotam Kolben · Hebrew University of Jerusalem1 papers (2023–2023) · 1 papers (2017–2017)Yishai Ofran · Rambam Health Care Campus1 papers (2016–2016)Amir A. Kuperman · Hebrew University of Jerusalem1 papers (2018–2018)Ziad Abdeen · American University in Cairo1 papers (2017–2017)Kalman Filanovsky · Hebrew University of Jerusalem1 papers (2016–2016)Naval Daver · The University of Texas MD Anderson Cancer Center1 papers (2021–2021) · 1 papers (2023–2023)Vikram Mathews · Massachusetts General Hospital1 papers (2024–2024) · 1 papers (2023–2023)